MedPath

The Mechanism of lncRNA NEAT1 in Alleviating Acute Respiratory Distress Syndrome Through miR-27b Regulated Nrf2 Pathway

Conditions
Acute Respiratory Distress Syndrome
Inflammation
Interventions
Other: no intervention
Registration Number
NCT04937855
Lead Sponsor
Beijing Anzhen Hospital
Brief Summary

The acute respiratory distress syndrome, formerly known as the acute lung injury (ARDS/ALI), is a critical illness with high mortality due to the lack of effective treatment. The pathogenesis of ARDS/ALI has not been fully elucidated. Nuclear factor E2-related factor 2 (Nrf2) plays a key role in regulating lung inflammation and oxidative stress which are closely related to lung injury in ARDS/ALI, but its regulatory mechanism remains unclear. The investigator's provious study shown that microRNA-27b (miR-27b) downregulated Nrf2 to aggravate lung inflammation and histological injury. Furthermore, in lipopolysaccharide (LPS)-induced cell (J774A.1) inflammation model, miR-27b was upregulated while the long non-coding RNA (lncRNA) NEAT1 was downregulated, the putative binding sites of lncRNA NEAT1 and miR-27b were successfully predicted by bioinformatics approach. Thus, the investigators propose that NEAT1 plays as a competing endogenous RNA (ceRNA) to adsorb miR-27b and liberate Nrf2, therefore, to attenuate lung inflammation and related lung injury in ARDS/ALI. This project aims to explore the role of the lncRNA NEAT1/ mir-27b /Nrf2 signal axis in the development and treatment of ARDS/ALI in patients, as well as in LPS-induced ALI animal and cell models by using bioinformatics, molecular biology, histomorphology and clinical phenotype approaches, and to clarify the new mechanism in ARDS/ALI development and to provide new therapeutic targets.

Detailed Description

Collect blood and BALF from 400 ARDS patients at different time (at check-in, 24, 48 and 72 h after check-in the hospital) and 25 gender and age matching healthy controls. Use RT-PCR to detect the expression of lncRNA NEAT1、miR-27b and Nrf2 in blood and BALF of ARDS patients and health controls. The expressions of inflammatory and oxidative stress associated factors (NLRP3、NF-κB-P65、 p-P65、IκB、p-IκB、HO-1、NQO1、caspase-1、IL-1β、IL-6、IL-18、TNF-α) will be detected by western blot、ELISA and RT-PCR. Moreover, flow cytometry will be adopted to measure the numbers and kinds of cells in BALF. Then, analyze the differences of the expressions of lncRNA NEAT1、miR-27b and Nrf2 in the groups. To explore the correlation of expressions of lncRNA NEAT1、miR-27b and Nrf2 with inflammation and oxidative stress in the groups. Finally, to declare the relative of lncRNA NEAT1、miR-27b and Nrf2 with the time of mechanical ventilation, severity and mortality in 28 days of ARDS patients.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
425
Inclusion Criteria

We included patients with acute respiratory distress according to 2012 ARDS Berlin new definition (Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA, 2012, 307(23):2526).

  • Acute or progressive dyspnea within 1 week with identify cause;
  • Chest radiograph/chest CT showed double lung infiltration, which could not be fully explained by pleural effusion, atelectasis, or nodules;
  • Respiratory failure cannot be fully explained by heart failure and fluid overload;
  • Hypoxemia, partial pressure of oxygen in arterial blood (PaO2)/oxygen fraction in air (FIO2) <150 mm Hg under PEEP ≥5 cm H2O, (mild ARDS: 200mmHg<PaO2/FiO2≤300mmHg, moderate ARDS: 100mmHg<PaO2/FiO2≤200mmHg, severe ARDS: PaO2/FiO2≤100mmHg);
  • 18~70 years old;
  • Agree to participate in the trial, and sign the informed consent.
Exclusion Criteria
  • Age less than 18 years old;
  • Time of hospital stay <24 h;
  • Pregnancy;
  • Using V-V ECOM;
  • Cardiac index <1.5L·ml.min-1.m-2;
  • Pulmonary resection;
  • Pulmonary embolism ;
  • Refused to participate in the study.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
ARDS group 3no intervention100 ARDS patients at the time of 48h after check in hospital
Control groupno intervention25 gender and age matching healthy controls
ARDS group 1no intervention100 ARDS patients at the time of check in hospital
ARDS group 2no intervention100 ARDS patients at the time of 24h after check in hospital
ARDS group 4no intervention100 ARDS patients at the time of 72h after check in hospital
Primary Outcome Measures
NameTimeMethod
the mortality in 28 days of ARDS patientsup to 28 day

Record the mortality in 28 days of ARDS patients

The expression of lncRNA NEAT1 in blood and BALF in all groupsup to 24 day

Use RT-PCR to measure the expression of lncRNA NEAT1 in blood and BALF in all groups

The expression of miR-27b in blood and BALF in all groupsup to 3 day

Use RT-PCR to measure the expression of miR-27b in blood and BALF in all groups

The expression of Nrf2 in blood and BALF in all groupsup to 3 day

Use RT-PCR and Wsetern blot to measure the expression of Nrf2 in blood and BALF in all groups

The expression of inflammatory factors(IL-1β、IL-6、IL-18、TNF-α) in blood and BALF in all groupsup to 3 day

Use RT-PCR and ELISA to measure the expression of inflammatory factors(IL-1β、IL-6、IL-18、TNF-α) in blood and BALF in all groups

The expression of oxidative stress associated factors in blood and BALF in all groupsup to 3 day

Use Western blot to measure the expression of oxidative stress associated factors(NLRP3、NF-κB-P65、 p-P65、IκB、p-IκB、HO-1、NQO1、caspase-1) in blood and BALF in all groups

The kinds of inflammatory cells in BALF and blood in all groupsup to 3 day

Use flow cytometry to detect the kinds of inflammatory cells(neutrophile、macrophage、 lymphocyte) in BALF and blood in all groups

The time of mechanical ventilation of patients in ARDS groupsup to28 day

Record the time of mechanical ventilation of patients in ARDS groups

The severity of ARDS patients in ARDS groupsup to 28 day

Record the severity(PaO2/FiO2、OI、S/F、OSI) of ARDS patients in ARDS groups

The numbers and kinds of inflammatory cells in BALF and blood in all groupsup to 3 day

Use flow cytometry to detect the number of inflammatory cells in BALF and blood in all groups

Secondary Outcome Measures
NameTimeMethod
The differences and correlation of the expressions of lncRNA NEAT1、miR-27b and Nrf2 in the groupsup to 28 day

Analyse the differences of the expressions of lncRNA NEAT1、miR-27b and Nrf2 in the groups, and to explore the relations between the three(lncRNA NEAT1、miR-27b and Nrf2) in different groups.

The correlation of expressions of lncRNA NEAT1、miR-27b and Nrf2 with inflammation and oxidative stress in the groups.up to 28 day

To explore the correlation of expressions of lncRNA NEAT1、miR-27b and Nrf2 with inflammation and oxidative stress in the groups.

The relative of lncRNA NEAT1、miR-27b and Nrf2 with the time of mechanical ventilation, severity and mortality in 28 days of ARDS patientsup to 28 day

To declare the relative of lncRNA NEAT1、miR-27b and Nrf2 with the time of mechanical ventilation, severity and mortality in 28 days of ARDS patients

Trial Locations

Locations (1)

Department of Respiratory and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath